ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
67.109,88
0,04%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ASLAN Pharmaceuticals Ltd (ASLN)

  7. ASLAN Pharmaceuticals Ltd (ASLN) News

ASLN

ASLAN Pharmaceuticals (ASLN)

ASLAN Pharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ASLN
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
07/05/202413h41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
11/03/202413h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
14/02/202422h45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
24/01/202413h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
08/01/202413h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
22/12/202322h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
08/12/202322h42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
27/10/202314h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
24/10/202314h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
16/10/202312h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
18/08/202313h33Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
11/08/202313h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
20/07/202313h55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
06/07/202314h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
06/07/202314h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
06/07/202313h59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
03/07/202322h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASLNASLAN Pharmaceuticals Ltd
28/04/202313h29Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/04/202323h27Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/04/202322h28Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
24/03/202312h33Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
24/03/202312h03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
20/03/202322h21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
10/03/202313h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
06/03/202323h11Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
03/03/202314h31Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
14/02/202322h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
04/01/202312h05Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
21/12/202212h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:ASLN

Kürzlich von Ihnen besucht

USOTC
SCNQY
Societatea Nationala de ... (PK)
BIT
P1VIJ1
NLBNPIT1VIJ1 20991231 23...
BIT
F18194
Vontobel Financial Produ...
EU
FR0014003JI2
Harmony French Home Loan...
ASX
SMCRB
TG
A285HT
Abertis Infraestructuras...
COIN
YOKOCHOGBP
BIT
P1Z3F5
NLBNPIT1Z3F5 20351221 26...
ASX
POD
Podium Minerals
UNSW3
YOUCETH
yOUcash
NYSE
XCT
Equity Securities Trust I
AMEX
SULR
SmartETFs Sustainable En...
BIT
P1VJM3
NLBNPIT1VJM3 20991231 62...
NASDAQ
SUSQ
NASDAQ
TQQQ
ProShares UltraPro QQQ
TSXV
SWX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten